Premium
Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma
Author(s) -
Sauer Maike,
Plütschow Annette,
Jachimowicz Ron D.,
Kleefisch Dominik,
Reiners Katrin S.,
Ponader Sabine,
Engert Andreas,
von Strandmann Elke Pogge
Publication year - 2013
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.23361
Subject(s) - medicine , lymphoma , hodgkin lymphoma , outcome (game theory) , oncology , baseline (sea) , biology , mathematics , mathematical economics , fishery
Hodgkin lymphoma (HL) has become one of the best curable cancers. However, better biomarkers are needed for outcome prediction that would allow protecting patients from over‐ or under‐dosing of treatment. Thymus and activation‐regulated chemokine/CCL17 (TARC) is highly and specifically elevated in this disease and has been proposed as possible biomarker in HL patients. In this study, we show that pretreatment TARC levels were associated with established clinical risk factors and predictive for response to treatment in a large cohort of HL patients treated in clinical trials by the German Hodgkin Study Group. Moreover, TARC levels also significantly contributed to a novel multivariate model predicting treatment response. These data clearly suggest an important role for this chemokine as biomarker in HL. Am. J. Hematol. 88:113–115, 2013. © 2012 Wiley Periodicals, Inc.